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Summary The aim of this study was to evaluate the effects of oral administration of
transglucosidase (TG) on postprandial glucose concentrations in healthy subjects. A randomized
placebo-controlled three-way crossover trial was separated by a washout period of more than
3 days. Twenty-one normal healthy volunteers, aged 30–61 years old (17 males and 4 females)
were selected for this study. The subjects’ health was assessed as normal by prestudy screen-
ing. All subjects received 3 types of test meals (3 rice balls: protein, 14.4 g; fat, 2.1 g; and
carbohydrate, 111 g: total energy, 522 kcal) with 200 ml water in which 0 mg, 150 mg, or
300 mg of TG was dissolved. Blood samples for estimating plasma glucose and insulin concen-
trations were collected before and every 30 min after the experiment. As compared to no TG
treatment, TG administration tended to prevent a postprandial increase in plasma glucose
(p = 0.069: 150 mg of TG vs control) but there were no significant difference among three
groups. With regard to the 17 subjects who were suggested to have impaired glucose tolerance,
TG significantly decreased the postprandial blood glucose (p<0.05: 150 mg and 300 mg of TG
vs control) and marginally decreased insulin concentrations (p = 0.099: 300 mg of TG vs
control). These results suggest that TG may be useful for preventing the progression of type
2 diabetes mellitus.
Key Words: transglucosidase, oligosaccharide, type 2 diabetes, postprandial hyperglycemia,
postprandial hyperinsuliemia
Introduction
Type 2 diabetes is a result of both insulin resistance and
insulin deficiency; epidemiological studies have revealed that
even in nondiabetic individuals, postprandial glycemia was
positively associated with the risk of not only hypertension
and cardiovascular events but also that of diabetes. Any
intervention during the impaired glucose tolerance phase that
reduces insulin resistance or protects the beta cells or both
will probably prevent or delay progression to diabetes. α-
Glucosidase inhibitors, which retard the rate of carbohydrate
digestion, delay glucose absorption, and reduce the post-
prandial increase in blood glucose, are being widely used
globally for treating diabetes. Moreover, these inhibitors
could delay the development of type 2 diabetes in patients
with impaired glucose tolerance [1–3].
A prospective cohort study and randomized clinical trials
have demonstrated that type 2 diabetes can be largely
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prevented by moderate diet and lifestyle modifications [4,
5]. Based on currently available data, increasing the intake
of dietary fiber can be recommended as a means of reducing
the risk of developing type 2 diabetes and cardiovascular
disease [6–8]. Dietary fiber, which includes oligosaccharides,
is known to be a factor that promotes good health and
prevents disease; it not only normalizes blood glucose and
insulin concentrations but also lowers blood cholesterol and
improves the microflora in the large intestine, which in turn
promotes normal laxation [9–11]. Insufficient intake of
dietary fiber is currently a major hindrance in the overall
promotion of health in the general Japanese population, as
well as that in the western countries including the United
States.
Transglucosidase (TG, α-glucosidase, enzyme code (EC)
3.2.1.20) is the enzyme that converts starch to oligosaccharides
via the action of amylase. This enzyme was shown to
synthesize oligosaccharides in the stomach. Therefore, the
administration of TG along with a meal is expected to
produce oligosaccharides in the digestive tract from the
starch present in the meal, lower the calorie intake, and
prevent the occurrence of diabetes in human subjects.
Furthermore, increasing the intake of oligosaccharides by
administering transglucosidase can also help to prevent the
progression of diabetes.
In this study, we have attempted to evaluate the effect of
administration of transglucosidase along with a meal on blood
glucose and insulin concentrations in healthy individuals.
Subjects and Methods
Materials
TG (3,000,000 U/g) was purchased from Amano Enzyme
Inc. (Nagoya, Japan). The test meal (rice ball) was
purchased from Lawson, Inc. (Tokyo, Japan).
Subjects
Twenty-one adults, aged 30–61 years old (17 males and 4
females), who were not under any drug therapy and were
judged to be healthy by an assessment of hearing including
about healthy check and a standard fasting blood analysis
that included peripheral blood cell count. According to
diagnosis criteria of diabetes mellitus of the committee of
Japan Diabetes Society, the estimations of blood glucose
concentration (<126 mg/dl) and glycosylated hemoglobin
(HbA1c) (<6.5%) were enrolled as volunteers in this study.
Ethical Committee of Nagoya City University Graduate
School of Medical Sciences granted approval for this study
and informed consent was obtained from all these subjects.
Procedures
Food intake was prohibited for 5 h prior to the experiment.
The 21 volunteers were divided into 3 groups. Each group
was sequentially given 3 different test meals which consisted
of 3 rice balls (protein, 14.4 g; fat, 2.1 g; carbohydrate,
111 g; total energy, 522 kcal), 3 rice balls along with 150 mg
of TG dissolved in water, or 3 rice balls along with 300 mg
of TG dissolved in water. The washout period for each type
of test meal was designed to exceed 3 days. A blood sample
was collected every 30 min from the time consuming the test
meal to 3 h after consuming the test meal (0 min, 30 min,
60 min, 90 min, 120 min, 150 min, 180 min) and then, the
plasma was separated for measuring the glucose and insulin
concentrations.
Assays
Plasma glucose, insulin, and HbA1c concentrations were
determined by using the glucose analyzer Glucoroder-NX
(Shino-Test Corporation, Tokyo, Japan), Modular Analytics
E170 (Roche Diagnostics Corp., Indianapolis, IN), and the
automated Glycohemoglobin Analyzer HLC-723G7 (Tosoh
Corporation, Tokyo, Japan), respectively. HbA1c was
assayed for the fasting blood sample collected for the
healthy check prior to the examination.
Calculation of Area Under Curve
The time course of blood glucose concentration or blood
insulin concentration after the intake of a test meal was
plotted, as shown in Figure 1. The area under curve (AUC)
was calculated by using the Trapezoid rule.
AUC = 1/2 × 0.5 × {(Yp +Y 0.5)+( Y 0.5 +Y 1.0)+( Y 1.0 +Y 1.5)
+( Y 1.5 +Y 2.0)+( Y 2.0 +Y 2.5)+( Y 2.5 +Y 3.0)}
(Y: consentration of serum glucose or insulin)
Statistical analyses
The AUC was calculated for the change in the serum
Fig. 1. Calculation of the area under curve (AUC). The areas
under curve for postprandial blood glucose and insulin
were calculated by using the following equation: 1/2
× 0.5 × {(Yp +Y 0.5)+( Y 0.5 +Y 1.0)+( Y 1.0 +Y 1.5)+( Y 1.5 +
Y2.0)+( Y 2.0 +Y 2.5)+( Y 2.5 +Y 3.0)}.Transglucosidase Prevents Postprandial Hyperglycemia
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glucose and insulin concentrations after the intake of each
test meal. Differences in the AUC were estimated by using
the paired t test. p values <0.05 were considered statistically
significant.
Results
Profiles of human subjects in this study
Table 1 lists the histories of the subjects who participated
in this study. The mean body mass index (BMI) suggests that
the subjects were slightly obese. The maximum HbA1c
among subjects was 6.4%, which was more than that of
nondiabetic individuals. The maximum fasting blood insulin
(FBI) value 36.7 µU/dL indicated that the study had
included insulin resistant individuals as subjects; however,
the maximum fasting blood glucose (FBG) value was
112 mg/dL, indicating that diabetic individuals were not
included as subjects in this study. The mean homeostasis
model assessment of insulin resistance (HOMA-IR) suggests
that subjects had insulin resistance.
Safety of the TG administration
There were no side effect-symptoms after TG administration.
Statistical analyses of AUC
The AUCs of blood glucose (AUCBG) for all the 21
subjects after consuming a test meal with or without TG
are shown in Fig. 2. The difference in the AUCBG was
statistically analyzed by using the paired t test. The AUCBG
that corresponded to the intake of the test meal with 150 mg
of TG had decreased marginally (p = 0.069) as compared
with the AUCBG that corresponded to the intake of the test
meal without TG. The AUCBG that corresponded to the
intake of the test meal with 300 mg of TG had tend to
decreased as compared with the AUCBG that corresponded to
the intake of the test meal without TG.
The AUCs of blood insulin (AUCBI) for all the 21 subjects
after the intake of a test meal with or without TG are shown
in Fig. 3; AUCBI had not changed significantly.
Statistical analyses of AUC for the high diabetes risk group
From among the 21 subjects, we selected 17 subjects
whose blood glucose (BG) after consuming the test meal
was more than 150 mg/dL and labeled them as the high
diabetes risk group. The AUCBG for the high risk group after
consuming a test meal with or without TG is shown in
Figure 4. The difference in the AUCBG was statistically
analyzed by using the paired t-test. The respective AUCBG
that corresponded to the intake of the test meals with 150 mg
of TG and 300 mg of TG had decreased significantly as
compared with the AUCBG that corresponded to the intake of
the test meal without TG (p<0.05 for 150 mg and 300 mg of
TG).
The AUCBI for the high risk group after consuming a test
meal with or without TG is shown in Fig. 5. The difference
Table 1.  Profiles of human subjects participating this study
Sex
Female/Male = 4/17
Mean ± SE Range
Age (y) 48.3 ± 8.4 30–61
Weight (kg) 70.9 ± 11.0 52–93
Height (m) 1.69 ± 0.07 1.47–1.77
BMI 24.7 ± 3.1 20.4–30.7
HbA1c (%) 5.4 ± 0.5 4.6–6.4
Hemoglobin (g/dl) 15.0 ± 1.2 12.7–17.2
FBG (mg/dl) 95.3 ± 10.8 77–112
FBI (mU/ml) 7.2 ± 8.3 1.0–36.7
HOMA-IR 1.56 ± 1.31 0.24–5.61
BMI: body mass index. FBG: fasting blood glucose. FBI: fasting
blood insulin. HOMA-IR: homeostasis model assessment of insulin
resistance.
Fig. 2. Statistical analyses of the AUCBG of all subjects. Intake
of 150 mg of TG along with the meal marginally
decreased the postprandial AUC for plasma glucose
concentration. Each value is expressed as mean ± SE
(p = 0.069, paired t test).
Fig. 3. Statistical analyses of the AUCBI for all subjects. The
postprandial AUC for plasma insulin level was not
changed after the intake of a test meal with or without
TG. Each value is expressed as mean ± SE (paired t test).M. Sasaki et al.
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in the AUCBI was statistically analyzed by using the paired
t test. The AUCBI that corresponded to the intake of the test
meal with 300 mg of TG had tended to decrease as
compared with the AUCBI that corresponded to the intake of
the test meal without TG (p = 0.099). However, the AUCBI
that corresponded to the intake of the test meal with 150 mg
TG did not decrease significantly as compared with the
AUCBI that corresponded to the intake of the test meal
without TG.
Discussion
The present study demonstrated a novel strategy that uses
dietary substrate to produce oligosaccharides in the digestive
tract; this strategy results in the flattening of postprandial
blood glucose and insulin responses.
α-Glucosidase (EC 3.2.1.20) catalyses the liberation of
glucose from the nonreducing ends of α-glucosides, α-linked
oligosaccharides, and α-glucans; additionally, α-glucosidase
is theoretically capable of catalyzing transglucosylation since
it retain glycosyl hydrolase [12].  Aspergillus niger  α-
glucosidase (transglucoaidase) that was used in this study
is an exo-type carbohydrolase with an optimum pH of
4–4.5 [13]; this enzyme catalyzes the following two
reactions: a transglucosylation reaction that forms panose
and isomaltooligosaccharide linked by 1,6-glucosidic
linkage from isomaltose, and a hydrolysis reaction with the
maltooligosaccharides as substrates, specifically those having
1,4-glycosidic linkages, that produces glucose [14–16]. We
have already demonstrated that transglucosidase can convert
carbohydrate to oligosaccharides in the gastrointestinal model
and gastric ligation rat models [17]. Furthermore, products
such as panose and isomaltooligosaccharide, which are
predominantly utilized by Bifidobacteria [16], are indigestible
oligosaccharides and reach the cecum.
In this study, we have proposed that the consumption of
transglucosidase can result in a reduction in the total amount
of orally-ingested calories due to the consequent transformation
of digestible substrate to indigestible fiber in the alimentary
tract. In this study, a single administration of transglucosidase
along with a meal decreased the postprandial AUC of blood
glucose and insulin concentrations in healthy subjects. Based
on the profiles of all the subjects, it can be stated that no
diabetic individuals were included in this study; however, the
subjects are likely to be slightly obese (BMI: 24.7 ± 3.1), and
17 subjects possibly had impaired glucose tolerance because
they had a high postprandial blood glucose concentration.
Particularly in these 17 subjects, TG intake caused a significant
reduction in postprandial hyperglycemia and marginally
hyperinsulinemia, thereby suggesting that it may improve
insulin sensitivity and release the stress on the beta calls.
Indigestible oligosaccharides normalize blood glucose and
insulin concentrations [18, 19] and are factors that promote
good health and prevent diseases, including type 2 diabetes
[9–11]. In addition, dietary fiber that includes oligosaccharide
has important effects; these include offering protection
against heart disease [6], improvement of the microflora in
the large intestine [20–26], prevention of colon cancer and
adenoma [27,  28], management of inflammatory bowel
disease [29, 30], inhibition of pathogens [31], and use in
cancer therapy [32].
The reduction in the total calorie intake and the effect of
oligosaccharide generated by transglucosidase can explain the
decrease in postprandial blood glucose and insulin secretion.
However, the former is probably mainly responsible for
the result of this experiment because a 3-h period after
consumption of transglucosidase may be insufficient to
produce the action of the oligosaccharide, which reacts after
Fig. 4. Statistical analyses of the AUCBG for the high diabetes
risk group. For the 17 subjects whose BG after consum-
ing a test meal was more than 150 mg/dL, administration
of both 150 mg and 300 mg of TG decreased the post-
prandial AUCBG significantly. Each value is expressed as
mean ± SE (p<0.05, paired t test).
Fig. 5. Statistical analyses of the AUCBI for the high diabetes
risk group. For the 17 subjects whose BG after consum-
ing a test meal was more than 150 mg/dL, postprandial
AUCBI was marginally decreased after consuming
300 mg of TG. Each value is expressed as mean ± SE
(p = 0.099, paired t test).Transglucosidase Prevents Postprandial Hyperglycemia
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reaching the cecum. Furthermore, former studies that reflect the
normalizing effect on blood glucose and insulin administered
the same more than 24 h before the administration of
oligosaccharide that was administered before blood sampling.
As the effects of 300 mg of TG had not changed from that of
150 mg, the dosage of 150 mg seems sufficient to reduce
postprandial hyperglycemia and even less dosage might be
effective.
We conclude that the main effect of the oral administration
of a single dose of transglucosidase along with a meal is
the decrease or delay in glucose absorption due to the
transformation of intestinal substrate to indigestible fiber. As
an increased risk for developing type 2 diabetes is associated
with conditions of overweight and obesity [33], a decreasing
the total energy intake as well as increasing physical activity is
recommended for preventing the conditions of overweight and
obesity. Furthermore, any intervention during the impaired
glucose tolerance phase that reduces insulin resistance and/
or protects the beta cells will probably prevent or delay its
progression to diabetes. Accordingly, the reducing effect of
transglucosidase on insulin resistance could prevent type 2
diabetes, and in a manner similar to the former antidiabetes
medicines such as α-glucosidase inhibitor [2], it is useful for
the prevention of type 2 diabetes.
Lifestyle changes (nutritional therapy and physical activity)
reduce the frequency of occurrence of diabetes [34]; however,
they demand great effort from the individuals. There is
little doubt that the long-term intake of transglucosidase
could be used to delay development of type 2 diabetes due
to its additive effects of decreasing calorie intake and
transglucosidase-related oligosaccharide effects. Further, it
is useful for protection against heart disease, improvement
of the microflora in the large intestine, prevention of colon
cancer and adenoma, treatment of inflammatory bowel
disease, inhibition of pathogens, and in cancer therapy.
However, since pharmacological prevention of type 2
diabetes was less beneficial than lifestyle modification,
including improving dietary habits and increasing physical
exercise [35]; thus, lifestyle modification and an improved
pharmacological approach are requisites to prevent develop-
ment of type 2 diabetes.
Abbreviations
TG, transglucosidase; BMI, body mass index; AUC, area
under curve; FBG, fasting blood glucose; FBI, fasting blood
insulin; BG, blood glucose; BI, blood insulin; HOMA-IR,
homeostasis model assessment of insulin resistance.
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